Synonyms: compound 5 [PMID: 28151659]
Compound class:
Synthetic organic
Comment: GSK2982772 is a first-in-class clinical candidate RIPK1 inhibitor, with anti-inflammatory potential [1]. X-ray structure of co-crystals shows GSK2982772 in a Type III-like kinase inhibitor position.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
GSK2982772 is in Phase 2 clinical trials in psoriasis (NCT02776033), rheumatoid arthritis (NCT02858492), and ulcerative colitis (NCT02903966). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02776033 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis | Phase 2 Interventional | GlaxoSmithKline | ||
NCT02858492 | Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) | Phase 2 Interventional | GlaxoSmithKline | ||
NCT02903966 | GSK2982772 Study in Subjects With Ulcerative Colitis | Phase 2 Interventional | GlaxoSmithKline |